Studies have shown that the NLRP3 inhibitor MCC950 significantly alleviates ligature-induced periodontitis, reduces IL-1β activation and osteoclast differentiation, and thereby inhibits alveolar bone resorption (He et al., 2020). Here, NLRP3 is linked to periodontitis.